Short Interest in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Drops By 43.4%

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) was the recipient of a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 106,500 shares, a decline of 43.4% from the January 31st total of 188,200 shares. Currently, 1.3% of the shares of the stock are sold short. Based on an average trading volume of 2,240,000 shares, the short-interest ratio is currently 0.0 days.

Cyclacel Pharmaceuticals Stock Down 2.7 %

Shares of CYCC stock traded down $0.01 during mid-day trading on Monday, hitting $0.32. 133,146 shares of the company’s stock were exchanged, compared to its average volume of 1,197,190. The stock has a market cap of $2.03 million, a price-to-earnings ratio of -0.03 and a beta of 0.35. The stock has a 50-day simple moving average of $0.36 and a two-hundred day simple moving average of $0.63. Cyclacel Pharmaceuticals has a fifty-two week low of $0.30 and a fifty-two week high of $4.00.

Insider Transactions at Cyclacel Pharmaceuticals

In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 194,628,820 shares of Cyclacel Pharmaceuticals stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total value of $5,838,864.60. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 23.97% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Cyclacel Pharmaceuticals in a research report on Thursday. They set a “sell” rating for the company.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.